David C Taussig

Summary

Affiliation: Queen Mary
Country: UK

Publications

  1. ncbi Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
    David C Taussig
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Blood 112:568-75. 2008
  2. ncbi Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction
    David C Taussig
    Cancer Research UK Medical Oncology Unit, St Bartholomew s Hospital, Queen Mary University of London, London
    Blood 115:1976-84. 2010
  3. ncbi Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
    David C Taussig
    Haematopoietic Stem Cell Laboratory, Cancer Research UK, London Research Institute
    Blood 106:4086-92. 2005

Detail Information

Publications3

  1. ncbi Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
    David C Taussig
    Department of Medical Oncology, St Bartholomew s Hospital, London, UK
    Blood 112:568-75. 2008
    ..More importantly, the work suggests that there is greater variation in the phenotypes of leukemia-initiating cells than previously suggested...
  2. ncbi Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction
    David C Taussig
    Cancer Research UK Medical Oncology Unit, St Bartholomew s Hospital, Queen Mary University of London, London
    Blood 115:1976-84. 2010
    ..This feature of LICs may make them particularly difficult to eradicate using therapies targeted against surface antigens...
  3. ncbi Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
    David C Taussig
    Haematopoietic Stem Cell Laboratory, Cancer Research UK, London Research Institute
    Blood 106:4086-92. 2005
    ..Our findings also provide a challenge to contemporary attempts to improve the outcome of AML using myeloid antigen-targeted therapies, given the potential for HSC killing...